Chaoming Li

Chaoming Li

Auto-generated profile, based on publicly available information

Chaoming Li

The First People’s Hospital of Longnan, Longnan City Hospital, Longnan, Gansu, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
WLWenfeng Lin
Wenfeng Lin
CLChaoming Li
Chaoming Li
NXNaijin Xu
Naijin Xu
MWMasami Watanabe
Masami Watanabe
RXRuizhi Xue
Ruizhi Xue
PHPeng HUANG
Peng HUANG
Purpose: With the advance of screening techniques, there is a growing number of low-risk or intermediate-risk prostate cancer (PCa) cases, remaining a serious threat to men’s health. To obtain better efficacy, a growing interest has been attracted to develop such emerging treatments as immunotherapy and focal therapy. However, few studies offer guidance on whether and how to combine these modalities against PCa. This study was designed to develop dual-functional nanoparticles (NPs) which combined photothermal therapy (PTT) with immunotherapy and determine the anti-tumor efficacy for PCa treatment. Methods: By a double emulsion technique, the drug nanocarrier, poly(lactic-co-glycolic acid) or PLGA, was applied for co-loading of a fluorescent dye, indocyanine green (ICG) and a toll-like receptor 7/8 (TLR7/8) agonist resiquimod (R848) to synthesize PLGA-ICG-R848 NPs. Next, we determined their characteristic features and evaluated whether they inhibited the cell viability in multiple PCa cell lines. After treatment with PLGA-ICG-R848, the maturation markers of bone marrow-derived dendritic cells (BMDCs) were detected by flow cytometry. By establishing a subcutaneous xenograft model of mouse PCa, we explored both the anti-tumor effect and immune response following the NPs-based laser ablation. Results: With a mean diameter of 157.7 nm, PLGA-ICG-R848 exhibited no cytotoxic effect in PCa cells, but they significantly decreased RM9 cell viability to (3.9± 1.0)% after laser irradiation. Moreover, PLGA-ICG-R848 promoted BMDCs maturation with the significantly elevated proportions of CD11c+CD86+ and CD11c+CD80+ cells. Following PLGA-ICG-R848-based laser ablation in vivo, the decreased bioluminescent signals indicated a significant inhibition of PCa growth, while the ratio of splenic natural killer (NK) cells in PLGA-ICG-R848 was (3.96± 1.88)% compared with (0.99± 0.10)% in PBS group, revealing the enhanced immune response against PCa. Conclusion: The dual-functional PLGA-ICG-R848 NPs under laser irradiation exhibit the anti-tumor efficacy for PCa treatment by combining PTT with immunotherapy.

20 July 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
JFJiaojiao Fu
Jiaojiao Fu
TQTian sheng Qin
Tian sheng Qin
CLChaoming Li
Chaoming Li
JZJiaojiao Zhu
Jiaojiao Zhu
YDYaoyao Ding
Yaoyao Ding
FCFan Chen
Fan Chen
The retrotransposon known as long interspersed nuclear element-1 (LINE-1), which is currently the sole autonomously mobile transposon in the human genome, can result in insertional mutations, chromosomal rearrangements, and genomic instability. In recent years, numerous studies have shown that LINE-1 is involved in the development of various diseases and also plays an important role in the immune regulation of the organism. The expression of LINE-1 in gynecologic tumors suggests that it is expected to be an independent indicator for early diagnosis and prognosis, and also, as a therapeutic target, LINE-1 is closely associated with gynecologic tumor prognosis. This article discusses the function of LINE-1 in the diagnosis, treatment, and prognosis of ovarian, cervical, and endometrial malignancies, as well as other gynecologic malignancies. It offers fresh perspectives on the early detection of tumors and the creation of novel anti-tumor medications.

1 January 2023
Verified
Conference Paper
Closed access
MWMingan Wang
Mingan Wang
CLChaoming Li
Chaoming Li
SYShili Yu
Shili Yu
Chong WangChong Wang
Chong Wang
XZXiaofang Zheng
Xiaofang Zheng
DSDeqiang Sun
Deqiang Sun

8 June 2022
Verified
Journal Article
Closed access
YLYun Li
Yun Li
NCNan Cui
Nan Cui
XXXing-Xing Xiong
Xing-Xing Xiong
ZHZhi-Yuan Huang
Zhi-Yuan Huang
ZLZe-Bing Li
Ze-Bing Li
JLJun Li
Jun Li